Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cenix BioScience Signs Multi-Project Research Agreement with AstraZeneca

Published: Tuesday, June 16, 2009
Last Updated: Tuesday, June 16, 2009
Bookmark and Share
The agreement expands relationship beyond its initial oncology focus, to now include respiratory and inflammation-related indications.

Cenix BioScience GmbH announced that they have signed a new multi-project research agreement with AstraZeneca, thereby expanding their relationship beyond its initial oncology focus, to now include respiratory and inflammation-related indications.

The new agreement calls for Cenix to complete at least three major projects applying the same platform for RNAi-based research.

The work will integrate multi-pass genome-scale screens for the discovery of novel therapeutic target candidates with detailed validation analyses, all using a number of primary human cell types.

Cenix will adapt assays initially developed by AstraZeneca scientists, combining several complementary technology platforms including automated microscopy with Cellenger-based image analysis, to optimize their implementation as high throughput RNAi studies in 384-well and/or 1,536-well formats.

“We particularly welcome the approach chosen by AstraZeneca here, of tightly integrating the discovery screens with subsequent validation studies, a strategy that we have been strongly advocating for some years,” said Dr. Christophe Echeverri, CEO/CSO of Cenix.

Dr. Echeverri continued, “We also greatly appreciate and value the continuing trust that is manifested by this expanded relationship, whose full potential we look forward to realizing together in the months and years to come.”

Financial terms were not disclosed.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cenix BioScience Signs Research Service Agreement with Bayer Pharma AG
Company will undertake a target discovery project for an undisclosed disease indication.
Tuesday, May 06, 2014
Cenix BioScience Joins EU FP7 Consortium for Discovery of miRNA Medicines
Company has joined an EU-funded consortium focused on the discovery of microRNA medicines in the area of cardiac and inflammatory metabolic diseases.
Wednesday, August 14, 2013
Cenix BioScience Expands Operations to U.S.
Company establishes new subsidiary named Cenix BioScience USA in Minnesota.
Friday, March 02, 2012
Cenix signs RNAi research agreement with SYGNIS
Cenix BioScience GmbH, announced it has signed a research agreement with SYGNIS Bioscience GmbH & Co. KG, a pharmaceutical company dedicated to developing innovative therapies for the treatment of disorders of the central nervous system.
Thursday, November 17, 2011
Cenix BioScience Signs Collaboration and Technology License Agreement for In Vivo siRNA Delivery
Collaboration and Technology License Agreement to improve the in vivo applicability of siRNA-based experimentation, focusing on the further co-development of DARE™.
Thursday, May 05, 2011
Cenix BioScience Joins EU FP7 Consortium
Consortium focused on improving the in vivo use of siRNA technology in the area of respiratory and inflammatory diseases.
Wednesday, March 30, 2011
Cenix BioScience Grows, Establishing New R&D Subsidiary in Flanders, Belgium
The new company accelerates the development of the company’s R&D capabilities in key growth areas including CNS-focused drug discovery and in vivo RNAi.
Saturday, January 15, 2011
Cenix BioScience Expands Relationship with AstraZeneca, Signing Multi-Project Research Agreement
The new agreement calls for Cenix to complete three major projects applying same platform for RNAi-based research.
Friday, June 26, 2009
InteRNA Technologies and Cenix BioScience Ink Research Agreement for miRNA Drug Discovery
The research agreement comprises functional screens in human cell lines using InteRNA’s proprietary library of miRNAs.
Tuesday, November 18, 2008
Scientific News
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
A Guide to CRISPR Gene Activation
A comparison of synthetic gene-activating Cas9 proteins can help guide research and development of therapeutic approaches.
Testing Non-Breast/Ovarian Cancer Genes
Researchers have found that expanding gene panel beyond breast/ovarian cancer genes in these patients does not add any clinical benefit. Instead, testing has produced more questions than answers.
Myeloid-Derived Suppressor Cells Play Role in Tumor Growth
Researchers at Baylor College of Medicine have reported a new mechanism that helps cancer cells engage myeloid-derived suppressor cells.
Cancer Cells Coordinate to Form Roving Clusters
Rice University scientists identify ‘smoking gun’ in metastasis of hybrid cells.
Poliovirus Therapy Wins 'Breakthrough' Status
FDA decision will fast-track research on breakthrough Duke brain cancer therapy.
Novel Way to Prevent Deadly Bacterial Infections
Monash scientists may have found a way to stop deadly bacteria from infecting patients. The discovery could lead to a whole new way of treating antibiotic-resistant “superbugs”
New Treatment for Pancreatic Cancer
Researchers at Purdue University have shown how controlling cholesterol metabolism in pancreatic cancer cells reduces metastasis.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!